Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Speculative biotech momentum setup: shares have broken out ~31% over 21 days (12.5→16.45) above prior consolidation, supported by fresh analyst coverage (Moderate Buy), new institutional buying and upcoming JPMorgan presentation. With resistance near ~17 and strong recent ROC, any positive clinical or corporate update could fuel a further momentum spike in the short term, though cash burn and lack of near-term data keep risk high.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: • Strong Liquidity • Persistent Losses • Share Dilution TNGX has exceptional liquidity and low debt but remains cash-burning and unprofitable, making its high valuation dependent on future revenue growth.
Price Behavior
Key Price Behavior Insights: • Persistent downtrend • Support breakdown • Recovery needed Support Level: $21.75 Resistance Level: $23.30–$24.00 TNGX remains bearish over the last month, with the break below $22.30–$22.50 shifting focus to holding $21.75, while a recovery above $23.30–$24.00 is needed to improve momentum.
Sentiment & News
Key News Insights: • Mixed institutional flows • Shares under pressure • No clinical catalyst Tango Therapeutics shares fell 6.2% amid mixed institutional trading and routine investor-relations and equity-compensation updates, with no new clinical or operational catalyst disclosed.
AI Summary
TNGX is now a concentrated, event-driven bet on whether vopimetostat's 92% early response signal with daraxonrasib can replicate with durable survival and acceptable safety in MTAP-deleted pancreatic cancer; its ~$1 billion liquidity runway reduces near-term financing risk, but the $4.4 billion valuation already demands convincing confirmatory data.
Description
Tango Therapeutics is a Cambridge, Massachusetts–based biotechnology company that discovers and develops small-molecule therapies for cancer. Its lead candidate, TNG908, is a PRMT5 inhibitor targeting tumors with MTAP deletions, and the pipeline includes inhibitors directed at USP1 for BRCA1/2-mutant cancers and a program for STK11-mutant tumors. The company maintains a strategic discovery and development collaboration with Gilead Sciences and was founded in 2017.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Mar 10 | Mar 17 | TNGX | Tango Therapeutics, Inc. | Speculative biotech momentum setup: shares have broken out ~31% over 21 days (12.5→16.45) above prior consolidation, supported by fresh analyst coverage (Moderate Buy), new institutional buying and upcoming JPMorgan presentation. With resistance near ~17 and strong recent ROC, any positive clinical or corporate update could fuel a further momentum spike in the short term, though cash burn and lack of near-term data keep risk high. | Closed | +13.2% |